Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Listen to expert discussions and interviews in pharma and biopharma.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Green-chemistry progesterone synthesis reduces carbon footprint by more than 70%
March 6, 2018
By: Kristin Brooks
Managing Editor, Contract Pharma
Pfizer CentreOne has introduced Enviero progesterone into the API marketplace. Enviero progesterone is produced by a first-of-its-kind progesterone synthesis developed by Pfizer that reduces waste, greenhouse gas emissions and use of hazardous solvents. Results include reducing the carbon footprint of the progesterone manufacturing process by more than 70 percent1 and eliminating the use of metal catalysts. Pfizer CentreOne, a global contract manufacturing organization embedded within Pfizer Inc., is a supplier of steroid and hormone APIs and intermediates. “Enviero green-chemistry progesterone represents a step change in progesterone API synthesis,” said Greg Scanlon, API business lead for Pfizer CentreOne. “And it’s in keeping with Pfizer’s commitment to reduce its impact on the environment.2 ”Developed over 12 years, Enviero (“En-VI-ro”) progesterone is manufactured via a proprietary biocatalytic3 process based on plant sterols. Scanlon continued, “We are pleased to offer Enviero progesterone to customers looking for a reliable supply of high-quality progesterone for their medicines.” While new to Pfizer CentreOne customers, Enviero progesterone has been used by Pfizer as an intermediate in the manufacture of its own medications for the past four years. More than 500 metric tons have been manufactured to date for internal use. The compound is manufactured exclusively in the U.S. at Pfizer’s Kalamazoo, MI, facility. All processing steps for Enviero progesterone are performed under Pfizer’s quality management system, and the compound is backed by technical and regulatory support for the life of the product. Enviero progesterone is the first API to be launched from Pfizer CentreOne’s green-chemistry program. According to the U.S. Environmental Protection Agency, “Green chemistry is the design of chemical products and processes that reduce or eliminate the use or generation of hazardous substances.”4 Green chemistry is applied at the process level – in this case, API synthesis – to minimize waste and pollution upfront. References:
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !